Skip to main content
. Author manuscript; available in PMC: 2019 Jun 13.
Published in final edited form as: Oral Oncol. 2018 Apr 17;81:45–51. doi: 10.1016/j.oraloncology.2018.04.008

Table 1.

Baseline tumor PD-L1 expression and HPV status.

Patients, n (%) Nivolumab (n = 240) IC (n = 121)
Tumor PD-L1 expression 40 (33.1)
 Non-expressors (< 1%) 76 (31.7) 40 (33.1)
 Expressors (≥1%) 96 (40.0) 63 (52.1)
 Not quantifiable 68 (28.3) 18 (14.9)
Tumor HPV status
 Positive 64 (26.7) 29 (24.0)
 Negative 56 (23.3) 37 (30.6)
 Unknown/not reported 120 (50.0) 55 (45.5)

IC, investigator’s choice; HPV, human papillomavirus; PD-L1, programmed death ligand 1.